Drug Profile
Research programme: caspase stimulants - OncoGenex Pharmaceuticals
Alternative Names: CSP-9222Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Developer OncoGenex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Caspase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 17 Apr 2012 CSP 9222 is still in preclinical development for Solid tumours